December 2010
1 post
6 tags
China Blog Series Part 4: Questions Still Remain
This is part 4 of a 4 part blog series featuring growth, challenges and predictions for China’s emerging life science industry:
Will Novartis’ USD 1 billion investment finally shame domestic Chinese pharmaceutical companies into making real commitments to innovative R&D?
The Chinese government, via funding programs such as the 863 National High Technology Research and...